Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Other Research And Development Expense

Other Research And Development Expense at other companies

Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$1.98M-36.4%
OS Therapies logo
OS TherapiesOSTX
$0—
RFL
Rafael Holdings, Inc.RFL
$22K-51.1%
CTO
Citius Oncology, Inc.CTOR
$469K-2.3%
TG Therapeutics logo
TG TherapeuticsTGTX
$87.27M+218%
TG Therapeutics logo
TG TherapeuticsTGTX
$87.27M+218%

Segments

By segment

See full
Reportable Segment$2.74M-21.3%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.3B+320%
Enterprise value$1.32B+474%

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×